Last reviewed · How we verify
high dose dual therapy
High dose dual therapy typically combines two active pharmaceutical agents at elevated doses to achieve synergistic therapeutic effects.
At a glance
| Generic name | high dose dual therapy |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Without specification of the exact agents, high dose dual therapy generally refers to a combination treatment strategy where two drugs are administered at higher-than-standard doses to enhance efficacy. This approach is often used in oncology, infectious disease, or cardiovascular conditions where combination therapy provides superior outcomes compared to monotherapy. The specific mechanism depends on the individual drugs and their molecular targets.
Approved indications
Common side effects
Key clinical trials
- EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc) (PHASE2)
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) (PHASE2, PHASE3)
- Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder (PHASE2)
- Assessment of TetraSOD® Efficacy to Improve Semen Parameters in Men With Idiopathic Infertility (NA)
- A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis (PHASE2)
- A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy (PHASE3)
- MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia (PHASE1)
- Study of LYL314 in Aggressive Large B-Cell Lymphoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- high dose dual therapy CI brief — competitive landscape report
- high dose dual therapy updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI